Royalty Pharma Officer Files Form 144 to Sell $235K in Shares Under Rule 10b5-1 Plan
Royalty Pharma plc
Subscribe to track RPRX
Premium users can add ticker alerts and receive realtime notification updates.
Filing Summary
š Form 144 Filed for Royalty Pharma plc ($RPRX) ā¢ Insider: Marshall Urist (Officer) ā¢ Proposed Sale: 4,126 shares ($235,594.60 value) ā¢ Broker: Merrill Lynch ā¢ Plan Adoption Date: June 26, 2026 ā¢ Recent Prior Sales: 13,225 shares sold in past 3 months ($747K+ proceeds)
Comprehensive Analysis
Transaction Summary
Royalty Pharma plc officer Marshall Urist filed a Form 144 on October 5, 2026, indicating an intention to sell 4,126 shares of Common Stock / Class A Ordinary Shares through Merrill Lynch. The approximate sale date is October 5, 2026, with an estimated aggregate market value of $235,594.60 (approximately $57.10 per share).
Key Details
- Acquisition Source: The shares proposed for sale were acquired on August 7, 2026, as an Equity Performance Award under the issuer's equity compensation program.
- Trading Plan: The filing notes an adoption date of June 26, 2026, for a pre-scheduled trading plan (Rule 10b5-1).
- Prior Sales Activity (Past 3 Months):
- July 1, 2026: 9,099 shares for gross proceeds of $508,453.82.
- September 28, 2026: 4,126 shares for gross proceeds of $238,812.88.
- Market Impact: With 445,277,344 units outstanding, this transaction represents less than 0.001% of the issuer's total shares, indicating minimal direct market impact.
Get Real-Time Alerts
Join our community to receive instant notifications when high-significance filings are published
Important Disclaimer
This content is drawn from public SEC filings and may contain errors. It is for informational purposes only and is not investment, legal, or tax advice.
Nothing here is a recommendation to buy, sell, or hold any security. Do your own due diligence.